Glycine

Glycine

SCHEMBL781340

CC(=O)O.CCCC.NCC(=O)O

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A known ✓ P27815 1/20 0.38
PDE3A known ✓ Q14432 1/20 0.38
OR51E2 Q9H255 2/20 0.62
GLRA1 P23415 1/20 0.62
SLC6A9 P48067 1/20 0.62
FFAR3 O14843 3/20 0.45
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44
GABRR1 P24046 1/20 0.39
AKR1B1 P15121 1/20 0.39
GPR84 Q9NQS5 7/20 0.38
PPARG P37231 7/20 0.38
PPARD Q03181 7/20 0.38
PPARA Q07869 7/20 0.38
HDAC11 Q96DB2 5/20 0.38
TSHR P16473 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycine SCHEMBL2231959 0.94
Glycine SCHEMBL318020 0.90
Glycine SCHEMBL29244710 0.90 GLRA1 (0.77) OR51E2GLRA1SLC6A9FFAR3HDAC3
Glycine SCHEMBL907052 0.90 GLRA1 (0.77) OR51E2GLRA1SLC6A9FFAR3HDAC3
Glycine SCHEMBL11291516 0.90 GLRA1 (0.77) OR51E2GLRA1SLC6A9FFAR3HDAC3
Glycine SCHEMBL7918812 0.90 GLRA1 (0.77) OR51E2GLRA1SLC6A9FFAR3HDAC3
Glycine SCHEMBL5535262 0.88 GLRA1 (0.62) OR51E2GLRA1SLC6A9FFAR3HDAC3
Glycine SCHEMBL19208039 0.88 GLRA1 (0.62) OR51E2GLRA1SLC6A9FFAR3HDAC3
Glycine SCHEMBL1285648 0.87 GLRA1 (0.71) OR51E2GLRA1SLC6A9FFAR3HDAC3
Glycine SCHEMBL20854478 0.87 GLRA1 (0.71) OR51E2GLRA1SLC6A9FFAR3HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305624-B1 Self-degradable explosive device MAXAMCORP HOLDING SL (ES) 2017-09-27 EP claimed
EP-2931278-A1 ORAL FORM, COMPRISING IMMEDIATE-RELEASE COATED PARTICLES OF AT LEAST ONE ACTIVE COMPOUND THAT ARE GRINDING-RESISTANT Flamel Ireland Limited (IE) 2015-10-21 EP claimed
US-9149439-B2 Multi-particulate, modified-release composition SANDOZ AG (CH) 2015-10-06 US claimed
WO-2014091437-A1 ORAL FORM, COMPRISING IMMEDIATE-RELEASE COATED PARTICLES OF AT LEAST ONE ACTIVE COMPOUND THAT ARE GRINDING-RESISTANT FLAMEL TECHNOLOGIES (FR) 2014-06-19 WO claimed
US-8585841-B2 Systems and methods for chemical and/or mechanical remediation of nitro compounds and nitrate esters MAXAMCORP HOLDING S.L. (ES) 2013-11-19 US claimed
EP-2445852-A1 SYSTEMS AND METHODS FOR CHEMICAL AND/OR MECHANICAL REMEDIATION OF NITRO COMPOUNDS AND NITRATE ESTERS Maxamcorp Holding, S.L. (ES) 2012-05-02 EP claimed
EP-2305624-A1 Self-degradable explosive formulations Maxamcorp Holding, S.L. (ES) 2011-04-06 EP claimed
US-20110041718-A1 SYSTEMS AND METHODS FOR CHEMICAL AND/OR MECHANICAL REMEDIATION OF NITRO COMPOUNDS AND NITRATE ESTERS MAXAMCORP HOLDING S.L. (ES) 2011-02-24 US claimed
WO-2010149750-A1 SYSTEMS AND METHODS FOR CHEMICAL AND/OR MECHANICAL REMEDIATION OF NITRO COMPOUNDS AND NITRATE ESTERS MAXAMCORP HOLDING S.L. (ES) 2010-12-29 WO claimed
US-5540945-A Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1996-07-30 US claimed
CN-116669665-A Intragastric expandable device 意比图密医疗有限公司 2023-08-29 CN disclosed
CN-112469398-A Pharmaceutical dosage form for oral administration with a sustained release effect 拜耳公司 2021-03-09 CN disclosed
EP-2305624-B1 Self-degradable explosive device MAXAMCORP HOLDING SL (ES) 2017-09-27 EP disclosed
US-20150328168-A1 ORAL FORM, COMPRISING IMMEDIATE-RELEASE COATED PARTICLES OF AT LEAST ONE ACTIVE COMPOUND THAT ARE GRINDING-RESISTANT FLAMEL IRELAND LIMITED (IE) 2015-11-19 US disclosed
EP-2931278-A1 ORAL FORM, COMPRISING IMMEDIATE-RELEASE COATED PARTICLES OF AT LEAST ONE ACTIVE COMPOUND THAT ARE GRINDING-RESISTANT Flamel Ireland Limited (IE) 2015-10-21 EP disclosed
US-5126142-A Sustained release of antibiotics to livestock ALZA CORPORATION (US) 1992-06-30 US disclosed
EP-0483273-A1 DISPENSER COMPRISING IONOPHORE. ALZA CORP (US) 1992-05-06 EP disclosed
EP-0425699-A1 ORAL PREPARATION WHICH CAN BE RELEASED AT SUITABLE REGION IN INTESTINE Chugai Seiyaku Kabushiki Kaisha (JP) 1991-05-08 EP disclosed
WO-1991001131-A1 DISPENSER COMPRISING IONOPHORE ALZA CORPORATION (US) 1991-02-07 WO disclosed
US-4186184-A Selective administration of drug with ocular therapeutic system ALZA CORPORATION (US) 1980-01-29 US disclosed